Promising Novel Agents for Aggressive B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the western world. Current treatment regimens result in curing approximately 50% to 60% of patients with DLBCL….
Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma
For initial staging and at end of treatment to document remission status, PET is the standard imaging modality. Interim scanning remains investigational. Surveillance PET is not beneficial in the majority…
Management of Relapsed Diffuse Large B-cell Lymphoma
Second-line therapy options for patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to, or relapses after, current rituximab-containing primary therapy continue to evolve. For younger patients, salvage therapy…
Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma presents as limited-stage disease in approximately 30% of cases. Historically, therapy relied on a combined modality of abbreviated chemotherapy followed by involved-field radiotherapy (IFRT). Due to…
Molecular Classification of Diffuse Large B-cell Lymphoma
Major progress in the understanding of diffuse large B-cell lymphoma (DLBCL) biology has been made in the last decade. Many specific compounds have now entered early phase clinical trials. However,…
State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents the most common lymphoid malignancy in adults, with a median age of 60 to 70 years. Clinical behavior is usually rapidly aggressive, with extranodal…
The Increasing Complexity of Aggressive B-cell Lymphoma
Laurie H. Sehn, MD, MPH, Editor Aggressive B-cell lymphoma is a descriptive term that has been applied to histologic subtypes of B-cell lymphoma that exhibit a rapid growth rate with…
Immunotherapy in Lung Cancer
The treatment of patients with good performance status and advanced stage non–small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents…
New Targets in Non–Small Cell Lung Cancer
With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non–small cell lung…
Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
Anaplastic lymphoma kinase ( ALK ) gene rearrangements occur in a small portion of patients with non–small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the…
